Skip to main content

Advertisement

Log in

Usefulness of glycated albumin in decisions regarding the discontinuation of a diabetes drug and factors associated with poor glycemic control following discontinuation in patients with type 2 diabetes mellitus

Diabetology International Aims and scope Submit manuscript

Abstract

We studied the usefulness of glycated albumin (GA) for decisions regarding the discontinuation of a diabetes drug in type 2 diabetic patients with good glycemic control, and the factors associated with increases in GA following discontinuation of a diabetes drug in patients with type 2 diabetes mellitus. Sixteen patients (12 males and 4 females) were enrolled in the present study and discontinued one diabetes drug. When the change in GA was less than 1 % at 4 weeks after the discontinuation of the diabetes drug (ΔGA4w), discontinuation was continued (the continuous group, n = 10), but when the change in GA was more than a 1 %, the discontinued diabetes drug was resumed (the resume group, n = 6). In the continuous group, HbA1c at 12 weeks after discontinuation (6.2 ± 0.6 %) remained unchanged from its value at discontinuation (6.2 ± 0.7 %) , but it was significantly elevated at 12 weeks after discontinuation in the resume group (changing from 6.3 ± 0.1 to 7.0 ± 0.6 %). Age, duration of diabetes, and GA were significantly lower while body mass index (BMI) was significantly higher in the continuous group than in the resume group, but no significant difference in HbA1c was observed between the groups. The discontinuation of a diabetes drug in patients with low insulin secretion must be performed carefully because factors such as duration of diabetes, BMI, and GA showed significant differences between the continuous group and resume group in our study, and these indicators are known to be linked with insulin secretion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Diabetes Association. Strategies for improving care. Diabetes Care. 2015;38:S5–7.

    Article  Google Scholar 

  2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.

    Article  Google Scholar 

  3. U.K. Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  4. Oishi M, Yamazaki K, Okuguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32). J Diabetes Investig. 2014;5:581–7.

  5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.

    Article  PubMed  Google Scholar 

  6. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. Am Fam Physician. 2013;87:331–6.

    PubMed  Google Scholar 

  7. Koga M. Glycated albumin; clinical usefulness. Clin Chim Acta. 2014;433:96–104.

  8. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care. 1995;18:440–7.

    Article  CAS  PubMed  Google Scholar 

  9. Takahashi S, Uchino H, Shimizu T, Kanazawa A, Tamura Y, Sakai K, et al. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1C) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J. 2007;54:139–44.

    Article  CAS  PubMed  Google Scholar 

  10. Hamaguchi T, Koga M, Murai J, Saito H, Tamada D, Kurebayashi S, et al. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for 2 weeks. J Diabetes Invest. 2012;3:175–8.

    Article  CAS  Google Scholar 

  11. Murai J, Soga S, Saito H, Koga M. Usefulness of glycated albumin for early detection of deterioration of glycemic control state after discharge from educational admission. Endocr J. 2013;60:409–13.

    Article  CAS  PubMed  Google Scholar 

  12. Koga M, Murai J, Saito H, Kasayama S. Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes. Diabetes Care. 2010;33:270–2.

    Article  CAS  PubMed  Google Scholar 

  13. Saisho Y, Tanaka K, Abe T, Shimada A, Kawai T, Itoh H. Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int. 2011;2:146–53.

    Article  Google Scholar 

  14. Ogawa A, Hayashi A, Kishihara E, Yoshino S, Takeuchi A, Shichiri M. New indices for predicting glycaemic variability. PLoS One. 2012;7:e46517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to national glycohemoglobin standardization program values. Diabetol Int. 2012;3:8–10.

    Article  Google Scholar 

  16. U.K. Prospective Diabetes Study Group. U.K. prospective study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.

    Article  Google Scholar 

  17. Koga M, Matsumoto S, Saito H, Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J. 2006;53:387–91.

    Article  CAS  PubMed  Google Scholar 

  18. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, et al. Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract. 2008;82:353–8.

    Article  CAS  PubMed  Google Scholar 

  19. Koga M, Hirata T, Kasayama S, Ishizaka Y, Yamakado M. Body mass index negatively regulates glycated albumin through insulin secretion in patients with type 2 diabetes mellitus. Clin Chim Acta. 2015;438:19–23.

    Article  CAS  PubMed  Google Scholar 

  20. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;79:291–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Norio Masumoto.

Ethics declarations

Conflict of interest

None.

Human rights and informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or a substitute for it was obtained from all patients prior to their participation in this study.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masumoto, N., Otsuki, H., Iwakawa, S. et al. Usefulness of glycated albumin in decisions regarding the discontinuation of a diabetes drug and factors associated with poor glycemic control following discontinuation in patients with type 2 diabetes mellitus. Diabetol Int 8, 39–44 (2017). https://doi.org/10.1007/s13340-016-0274-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-016-0274-y

Keywords

Navigation